



Understanding the Evolutionary Dynamics and Ecology of Cancer in Treatment Resistance

Guest Editor:

Prof. Dr. David Basanta

Integrated Mathematical
Oncology department, H. Lee
Moffitt Cancer Center & Research
Institute, 12902 Magnolia Drive,
Tampa, FL-33612, USA

Deadline for manuscript
submissions:

closed (31 March 2022)

Message from the Guest Editor

Dear Colleagues,

As the importance of somatic evolution in driving cancer initiation and progression is being increasingly recognized, we are now in a place where we can begin to understand its potential role in treatment. Virtually all advanced tumors become resistant to clinically available treatments. Evolution and ecology are key elements in explaining this resistance: in a sufficiently heterogeneous tumor, certain tumor cells will always avoid the full impact of the treatment. This could be the result of insufficient delivery due to the microenvironment, the cells having a (relative) degree of resistance to said treatment through genetic and epigenetic mechanisms, or as a result of the interactions between tumor cells with cells in the stroma. A better understanding of these factors could help us delay or even prevent the emergence of resistance and, potentially, to steer the evolution of the tumor towards clinically desirable outcomes in a patient-specific manner.

For this Special Issue of *Cancers*, we invite research articles and focused reviews on all aspects of cancer evolution and ecology related to treatment.

Prof. Dr. David Basanta
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)